Search Videos and More
News
Study Finds Racial Inequities in Access to Opioids Among Older Patients With Cancer Near End of Life
Older Black and Hispanic patients with advanced cancer are less likely to receive opioid medications for pain relief in the last weeks of life than White patients, a new study led by Dana-Farber Cancer Institute investigators found.
News
New Receptor “Decoy” Drug Neutralizes COVID-19 Virus and Its Variants
Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant.
News
Three-Drug Combination Therapy Effective in Patients with High-Risk CLL, Trial Shows
A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.
News
Research With a Worldwide Reach
Around the world, Dana-Farber's Susan F. Smith Center for Women's Cancers is known not just for its exceptional patient care, but also for the driving force its physician-scientists play in developing new paradigms of cancer treatment through pioneering research and clinical trials.
News
Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/Oncologists
As patients with cancer increasingly receive treatment in community hospitals and clinics and many such centers experience a shortage of oncologists, a group of physicians at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School has proposed the first-ever training blueprint for oncologists planning careers in a community or academic-community setting.
Video
SABCS 2022: Sara Tolaney, MD, MPH
Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and trastuzumab confirm excellent long-term outcomes for small, node-negative HER2-positive breast cancer.
Video
SABCS 2022: Paolo Tarantino, MD
ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.
Video
SABCS 2022: Ann Partridge, MD, MPH
Ann Partridge, MD, MPH, led the study presented at the 2022 San Antonio Breast Cancer Symposium which showed most women participating in the study went on to deliver healthy babies.
Video
SABCS 2022: Rachel Freedman, MD, MPH
Rachel Freedman, MD, MPH, shared results from the TBCRC 022 study where Neratinib in combination w/T-DM1 showed promising activity in patients w/heavily pre-treated HER2+ breast cancer metastatic to the central nervous system.
News
Study Finds That Risk of Adverse Side Effects From Cancer Immunotherapy is Higher in Patients with Certain Inherited Genetic Variations
Even as they've revolutionized cancer treatment, drugs known as immune checkpoint inhibitors can produce a range of adverse, immune-related side effects. In a new study, scientists at Dana-Farber Cancer Institute identify, for the first time, inherited genetic variations that place patients at high risk for these complications.
News
Dana-Farber Research Publication 12.15.2021
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia
A head-to-head clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has found that zanubrutinib, a next-generation BTK inhibitor, was more effective at preventing disease progression and better tolerated than ibrutinib, the first-generation BTK inhibitor that is the current standard treatment in that setting.